EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 336 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR The Galleri multi-cancer blood test: what you need to know September 13, 2021 EMA Starts Review of Rucaparib May 19, 2022 Cancer Researchers Bring Tools, Experience to COVID-19 Studies February 12, 2021 Veteran Drops To The Ground When He Hears How Much His... January 31, 2020 Load more HOT NEWS FDA Approves Imetelstat for Low- To Intermediate-1 Risk Myelodysplastic Syndromes with... Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation Meteorologist Uses Sign Language To Tell All Of Her Weather Forecasts
